Clinical Trials Directory

Trials / Terminated

TerminatedNCT03365076

Exercise for Improving Prostate Oxygenation in Prostate Tumors (Exipox)

Exercise for Improving Prostate Oxygenation in Prostate Tumors (Exipox)-Study - a Pilot Study Exploring Exercise as a Way of Improving Cure With Radical Radiotherapy

Status
Terminated
Phase
N/A
Study type
Interventional
Enrollment
1 (actual)
Sponsor
University Hospital of North Norway · Academic / Other
Sex
Male
Age
18 Years
Healthy volunteers
Not accepted

Summary

Previous research into metabolic and hypoxic markers has found evidence of preclinical impact of exercise on prostate tumor blood flow and oxygenation in rodents . As radiotherapy is a frequently used and effective therapy for and that sufficient oxygenation is decisive to the effect of radiotherapy, an underlying hypothesis that aerobic exercise might improve treatment efficacy of radiotherapy in prostate cancer is put forward. This study has a potential challenging intervention, but a potential very high gain as it includes active patient participation to significantly improve outcome of radical radiotherapy.

Detailed description

A randomized controlled trial with four to five weeks of moderate/high intensity aerobic exercise program compared with no intervention for 32 prostate cancer patients waiting for radical prostatectomy at the University Hospital of North Norway (UNN). 16 patients will undergo the intervention. The expression of the hypoxic marker pimonidazole in the prostate specimens of intervention groups and the control groups will be assessed. This method is considered a reliable tissue oxygenation measurement technique. These patients will also have their and blood flow and hypoxia measured in prostate cancers through magnetic resonance imaging (MRIs).

Conditions

Interventions

TypeNameDescription
OTHERPhysical activityAerobic physical activity as stated in Arm A

Timeline

Start date
2018-05-01
Primary completion
2023-01-05
Completion
2023-01-05
First posted
2017-12-07
Last updated
2023-01-09

Locations

1 site across 1 country: Norway

Source: ClinicalTrials.gov record NCT03365076. Inclusion in this directory is not an endorsement.